Prevalence and Risk Factors for Cervical Cytology Abnormality in General Female Population in Qujing of Yunnan Province, China
Sun Lu-lu,Cheng Xue-mei,Li Hui,Zhou Xian-rong,Song Zhi-qin,Shen Keng
DOI: https://doi.org/10.3760/cmaj.issn.0366-6999.20122330
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:Cervical cancer is the second most common cancer in women worldwide. There is a strong and consistent association of genital HPV infection with cervical cancer and its precancerous lesions.1 This study was undertaken to describe the prevalence of cytological abnormality in relation to HPV infection in general female population of Qujing city, Yunnan province, southwest China. METHODS Study population During June 2010-July 2010, 5936 women were sampled from resident women aged 18-65 years old in Qujing by multi-stage stratified cluster sampling method. Participants completed a questionnaire and cervical samples were collected for cytology diagnosis, HPV DNA test and HPV genotyping. Laboratory methods Cytological slides were first scanned by the ThinPrep Imaging System (Cytyc Corp., Boxborough, Massachusetts, USA). Marked field of view (FOV) was diagnosed by two pathologists. Abnormal cytology was defined as atypical squamous cell (ASC), glandular cell (AGC) and severe lesions, which were verified by expert pathologist. Cases with cytology abnormality were informed for colposcopy and biopsy. High risk HPV DNA was tested by the Digene Hybrid Capture 2® (HC2), which detects 13 HR-HPV genotypes including HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. Genotyping of HC2 positive samples was carried out using digene HPV Genotyping Reverse Hybridization Test. It detects 18 high risk or probably high risk HPV genotypes, in which HPV-26, 53, 66, 73 and 82 are not included in the current HC2 probe cocktail. Typespecific prevalence included that in both single-type and multiple-type infection. Ethical approval was granted by the Research Ethics Committee of PUMCH, Peking Union Medical College & the Chinese Academy of Medical Sciences. Statistical analysis SAS 8.0 System (SAS Institute Inc., USA) was employed. Frequencies were compared by χ2 tests. Multivariate model was calculated by stepwise elimination of candidate variables. P <0.05 denoted statistical significance. RESULTS Overall characteristics of participants Total 5936 women were included, 97.3% of whom was Han nationality. The median age was 38 years and the inter-quartile range was from 31 years to 47 years. 73.1% of participants had never heard of cervical cancer, 87.0% had never heard of cervical cytology screening, 90.2% had never heard of HPV. Only 4.7% of participants had cervical cancer screening before. Prevalence of cytological abnormality Prevalence of cytological abnormality was 5.8% (344/5936). ASC accounted for 3.7% (218), LSIL 1.2% (71), HSIL 0.66% (39), SCC 0.05% (3), AGC 0.17% (10) and AC 0.05% (3), respectively (Table 1).Table 1: Age-specific prevalence (% (n)) of cytological abnormality and HR-HPV infection (n=5936)Prevalence of ASC in 18-24 years age-group was relatively high (3.74%), which increased rapidly from 30-34 years (2.97%) to a maximum in 40-44 years (4.67%), and decreased gradually in women over 45 years old. Prevalence of LSIL increased gradually in 18-24 years (1.07%) to a maximum in 35-39 years (1.64%), and the second peak observed in 50-54 years (1.57%) and then decreased gradually. There was a relatively low prevalence of LSIL in 40-44 years age-group (0.74%). Prevalence of HSIL showed the same trend as LSIL from 18-24 to 35-39 years, with the first peak in 35-39 years (0.87%) and the second peak in 55-59 years (1.57%) that preponderate over prevalence of LSIL for the first time, then decreased gradually. Prevalence of cervical abnormality in relation to HPV infection Age-specific prevalence of cytological abnormality and HR-HPV infection was shown in Table 1 and Figure 1. Overall prevalence of HR-HPV infection (8.3%) was higher than that of cytological abnormality (5.8%). Prevalence of cytological abnormality of any grade showed one peak of 7.3% (CI 5.8%−8.9%) at age of 35-39 years and declined steadily from 6.4% (CI 4.7%−8.1%) at the age of 45-49 (χ2=82.320, P<0.0001). HR-HPV infection showed two peaks of 11.5% (CI 8.3%−14.7%) in women 18-24 years old and 11.2% (CI 8.1%−14.4%) in women 55-59 years old. The first five most prevalent HR-HPV types of participants were: HPV-16 (3.4%), HPV-56 (1.7%), HPV-58 (1.4%), HPV-33 (1.2%) and HPV-52 (0.88%), respectively. The OR of type specific HPV infection for HISL was as follows: HPV-33 (OR: 381.06, CI 68.88-2108.02), HPV-58 (OR: 61.18, CI 28.03-133.54), HPV-16 (OR: 47.29, CI 23.11-96.76), HPV-52 (OR: 17.06, CI 7.30-39.86) and HPV-56 (OR: 13.62, CI 4.00-46.34). In multiple HPV infection, the odds ratios of cytology abnormality were higher than that in single HPV infection (OR: 699.11, CI 190.30-2568.32; OR: 196.35, CI 59.00-653.33 in HSIL). Multivariate logistic regression analysis indicates that HR-HPV infection (OR: 19.7, CI 17.78-26.25), age of 50-54 years old (OR: 1.68, CI 1.09-2.58), smoking (OR: 1.96, CI 1.05-3.65) and trichomoniasis are risk factors for cytological abnormality. Age of 35-39 (OR: 0.64, CI 0.46-0.91) is a protective factor.Figure 1.: Comparison of age-specific prevalence of cytological abnormality and HPV infection (n=5936).HPV carriers without cervical abnormality The prevalence of HR-HPV carriers without cervical abnormality was 5.7% (318/5592). The first eight HPV genotypes of HPV carriers were: HPV-52 (25.4%), HPV-16 (20.9%), HPV-58(11.9%), HPV-56 (11.6%), HPV-35 (11.2%), HPV-33 (8.6%), HPV-18 (7.1%), and HPV-68 (4.9%), respectively. DISCUSSION The prevalence of cytological abnormality in general female population of Qujing (5.8%) was similar with 6.2% in previous study of non-Tibetan women in Tibetan Autonomous Region of China.2 Both areas located in western China with high altitude and limited medical resources. Only 4.7% of the study population had participated in cervical cancer screening before, and HSIL or more severe abnormality accounted for 13.1% of cytology abnormality. It is significant to undertake cervical cancer screening program in western China. The age-specific prevalence of cytological abnormality was the highest at age 35-39 (7.3%), which was correlate with frequent sexual activity and high prevalence of HPV infection of that age period.3 It should be emphasized that the high prevalence of cytological abnormality of this age resulted from interactions of numerous factors. Age itself acts as an individual protective factor, while there are much stronger risk factors, such as persistent high risk HPV infection result in this phenomenon. A strong and consistent association of HR HPV infection with cervical cancer and its precancerous lesion was revealed.4 Multivariate logistic regression in this study indicated that HPV infection was the strongest risk factor for cytological abnormality. One research demonstrated that HPV-52 and -58 were more predominant and overrepresented in Asian cervical cancer cases.5 In this study, the role of HPV-33 and HPV-58 was emphasized to point out that HPV vaccine investigation of Chinese should based on HPV genotypes of China. It is suggested that HPV prophylactic vaccines including HPV-33 and HPV-58 may offer higher protection for Chinese women. Furthermore, the effect of multiple HPV infection on etiology of cervical cancer was ambiguous. In this study, odds ratio for cytology abnormality in multiple HPV infection was higher than that in single HPV infection. Moreover, the prevalence of HPV carriers without cervical abnormality was 5.7%, which varied from 1.6% to 14.2% in other Asian countries.5 It is necessary that a cohort study be designed to determine the natural history of HRHPV infection and the role of multiple HPV infection in the development of cervical cancer.